Imagion Biosystems to Issue 17.9 Million Shares on Loan Conversion with Shareholder Approval

Executive Chairman Loan and Equity Conversion Details

Imagion Biosystems disclosed a USD$150,000 loan from its Executive Chairman under a loan agreement announced concurrently through a separate update. The loan terms specify that if the company does not repay the amount by a designated date, the outstanding balance will convert into ordinary fully paid shares. This conversion provides the Executive Chairman with a contingent equity stake, substituting traditional debt repayment with equity issuance.

The conversion calculation is based on multiplying the USD$150,000 loan by a fixed USD/AUD exchange rate of 1.43 and dividing by the share price of AUD$0.012 recorded on 24 June 2026, resulting in the proposed issuance of 17.9 million shares. Using a fixed historical exchange rate and share price ensures certainty in the conversion ratio and eliminates valuation variability post-agreement. The announcement does not disclose the original loan term, repayment deadline, or interest rate.

Shareholder Approval Process and ASX Listing Rule Compliance

Shareholder approval for the placement will be sought under ASX Listing Rule 7.1 at a meeting scheduled for 30 July 2026. The company confirmed that shareholder consent is a prerequisite for unconditional placement completion, with 30 November 2026 as the determination date. This timeline allows investors to evaluate and vote on the capital structure change prior to share issuance.

The placement does not involve any parties covered under Listing Rule 10.11, meaning no additional related-party transaction requirements apply beyond Listing Rule 7.1. The new shares will not be restricted securities and are not subject to voluntary escrow, enabling full tradability upon issuance. Imagion Biosystems will issue a cleansing notice under relevant sections of the Corporations Act to facilitate compliant secondary sales within 12 months.

Valuation and Pricing Methodology for the Share Placement

The estimated AUD$214.5 million valuation of the share issuance is derived from converting the USD$150,000 loan at a 1.43 exchange rate and dividing by the historical share price of AUD$0.012 as of 24 June 2026. This approach fixes the conversion ratio to a past share price rather than current market levels, reflecting the loan-to-equity conversion’s fixed terms. The announcement does not clarify if this price reflects typical trading levels around that date or the rationale for the reference date choice.

The substantial estimated value relative to the USD loan amount results from currency conversion and the low share price used. Actual shares issued will depend on the outstanding loan amount and exchange rate at conversion, which may differ from current estimates.

Purpose and Structure of the Capital Raise

The share issuance aims to settle the Executive Chairman’s outstanding loan if repayment is not made. This contingent equity structure offers an alternative to cash repayment or refinancing, potentially diluting existing shareholders if conversion occurs. The announcement does not specify the loan’s original use, funding date, or default events triggering conversion.

By structuring the funding as a loan with conversion rights, the company retains repayment flexibility before the conversion date. However, this creates uncertainty for shareholders regarding future dilution, influenced by the company’s financial position and USD/AUD exchange rate changes. No changes to dividend or distribution policies are planned, and no significant fees beyond those disclosed are expected.

Timeline for Shareholder Approval and Share Issuance

Imagion Biosystems set a shareholder meeting for 30 July 2026 to approve the placement, two days after the announcement dated 28 July 2026. The share issuance is targeted for 30 November 2026, allowing approximately four months between approval and issuance for assessment of market conditions and loan status.

The brief interval between announcement and shareholder meeting indicates prior preparation and anticipated support. The determination date aligns with the issuance date, confirming that conversion depends on shareholder approval by 30 November 2026. Investors should review full disclosures before voting.

Ranking and Market Trading of New Shares

The proposed shares will be added to the existing ordinary fully paid share class (ASX:IBX) and will rank equally with current shares in voting, dividend, and economic rights. This ensures no new share class or differentiated rights are created.

No new-class quotation application is needed as shares belong to an existing ASX class. The company will apply for quotation post-issuance by lodging an Appendix 2A form per Listing Rule 3.10.3C. There are no trading restrictions or escrow arrangements, ensuring full liquidity once the cleansing notice is published.

Loan Disclosure and Related-Party Information

The loan from the Executive Chairman was disclosed separately on the same date, providing transparency on both the loan and its equity conversion implications. The USD$150,000 loan is modest, but the 17.9 million shares proposed for conversion represent a significant impact on capital structure.

Details about the Executive Chairman’s shareholding, voting agreements, or other related-party arrangements were not provided. Imagion Biosystems operates in the biosystems sector, but this announcement does not detail its business model or financials. Investors should consult additional disclosures for context on the loan’s strategic purpose.

Share Dilution Risks and Conversion Uncertainty

The share placement poses dilution risks to existing shareholders if the loan is not repaid, reducing voting power, economic interest, and earnings per share. Dilution magnitude depends on total shares outstanding at conversion, which may change due to other capital events.

The announcement omits details on loan repayment timing, current liquidity, or hedging of USD/AUD exchange risk. Shareholders face uncertainty about conversion likelihood versus cash repayment or refinancing. The fixed 1.43 exchange rate protects the Executive Chairman from AUD depreciation but may cause gains or losses depending on actual rates at conversion. Lack of loan term, interest, and covenant details limits assessment of conversion probability.

Market Impact and Capital Management Considerations

The 17.9 million share placement will significantly increase Imagion Biosystems’ share count if approved and conversion occurs. The announcement’s market impact is unclear, but potential dilution could influence investor sentiment ahead of the shareholder meeting. Simultaneous loan and placement disclosures provide market clarity on debt and equity implications.

Structuring the Executive Chairman’s funding as a convertible loan rather than direct equity issuance suggests a preference to preserve shareholder approval capacity and capital management flexibility. However, contingent dilution introduces uncertainty regarding future capital structure. Investors and analysts will likely assess the company’s repayment ability and conversion risk based on financial and operational data. The next key event is the shareholder approval meeting on 30 July 2026.